

## Special Issue

# mRNA-Based Cancer Immunotherapy

### Message from the Guest Editor

Following the overwhelming success of mRNA-based vaccination in the COVID-19 pandemic, the focus of this technology has moved forward to alternative targets, including treatment of cancer. The major, initial hurdles for mRNA-based vaccines, such as instability of mRNA, inefficient delivery, weak immunogenicity, and large-scale production, have been resolved for the COVID-19 indication. For cancer, however, these issues need to be readdressed but should, hopefully, not constitute a major obstacle. In cancer indications, other challenges have to be overcome, such as selection of the tumor type, status and disease stage of patients, antigen(s) selection, packaging of the product (e.g., again using nanomaterials), route of administration, and immunological response and side effect rates. An additional important aspect that needs to be addressed is the feasibility of prophylactic administration of mRNA vaccination with the final objective of making therapeutic use no longer necessary. Authors in the field of mRNA-based immunotherapy are cordially invited to submit original research or review articles contributing to this important and fast-progressing area of biomedicine.

### Guest Editor

Dr. Werner Krause  
Bayer Pharma AG, Berlin, Germany

### Deadline for manuscript submissions

closed (31 October 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/136211](https://mdpi.com/si/136211)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).